ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel ...

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel ...

NEW YORK, April 19, 2025 (GLOBE NEWSWIRE) -

EIX DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Edison International Investors to Secure Counsel Before Important April 21 Deadline in Securities Class Action First Filed by the Firm – EIX - Edison Intl (NYSE:EIX)

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edison International (NYSE:EIX) between February 25, 2021 and February 6, 2025, both dates inclusive (the "Class Period"), of the important April 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Edison securities during the Class Period you may b…

TOP RANKED ROSEN LAW FIRM Encourages Everus Construction Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

NEW YORK, April 18, 2025 /PRNewswire/ -

UNH Investor News: Rosen Law Firm Encourages UnitedHealth Group Incorporated Investors to Inquire About Securities Class Action Investigation

NEW YORK, April 18, 2025 /PRNewswire/ -

Capital Research Global Investors Decreases Stock Position in UnitedHealth Group Incorporated (NYSE:UNH)

Capital Research Global Investors cut its holdings in UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 0.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 17,966,490 shares of the healthcare conglomerate’s stock after selling 15,806 shares during the quarter. UnitedHealth Group comprises approximately 1.9% of Capital Research Global Investors’ portfolio, making the stock […]

#Zenas BioPharma Under Fire: Stock Options for New Executives Amid Financial Woes and Legal Scrutiny,

Zenas BioPharma's Stock Options Riddle Amid Financial Scrutiny By Author Name | CSI Market April 18, 2025 ' In a move that has raised eyebrows within the biopharmaceutical community, Zenas BioPharma, Inc. (Nasdaq: ZBIO) announced on April 15, 2025, the granting of nonqualified stock options to two newly hired executives. This decision was made in accordance with Nasdaq's Listing Rule 5635(c)(4) and purportedly serves as an inducement for these o…